Clinical Trials/NCT01182142

NCT01182142

Completed

Phase 2

Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients

Kidney Cancer Research Bureau1 site in 1 country51 target enrollmentSeptember 2007

ConditionsMetastatic Renal Cell Carcinoma

InterventionsCapecitabine

DrugsCapecitabine

Overview

Phase: Phase 2
Intervention: Capecitabine
Conditions: Metastatic Renal Cell Carcinoma
Sponsor: Kidney Cancer Research Bureau
Enrollment: 51
Locations: 1
Primary Endpoint: Overall response rate
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.

Registry

clinicaltrials.gov

Start Date

September 2007

End Date

August 2010

Last Updated

15 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Kidney Cancer Research Bureau

Eligibility Criteria

Inclusion Criteria

•histologically confirmed non-clear cell renal cell carcinoma
•confirmed metastatic sites
•no chemotherapy in history

Exclusion Criteria

•metastases in CNS
•previous targeted therapy
•other tumor

Arms & Interventions

Capecitabine

All patients will receive capecitabine.

Intervention: Capecitabine

Outcomes

Primary Outcomes

Overall response rate

Time Frame: 12 months

Secondary Outcomes

Overall survival Progression-free survival(24 months)

Study Sites (1)

Loading locations...

Similar Trials

Capecitabine For Nasopharyngeal CancerHead and Neck Cancer

NCT00095901Dana-Farber Cancer Institute3

Phase II study of chemotherapy with Capecitabine/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer

JPRN-UMIN000010200Yamafuchi University Medical Bioregulation Department of Organ Regulatory Surgery30

Phase II trial of capecitabine for brain metastasis of breast cancerbrain metastasis of breast cancer

JPRN-UMIN000001530ational cancer center hospital32

Active, not recruiting

Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom - AIO KRK 0105

EUCTR2005-001919-21-DEMartin-Luther-Universität Halle-Wittenberg, Medizinische Fakultät, endvertreten durch den Dekan80

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomasNeuroendocrine Carcinoma

NCT03387592Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori53